Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07624747 · ClinicalTrials.gov registry record
Brain Health in Transgender Adults
A clinical trial, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 72
- Enrollment target
NCT07624747: Recruiting study, sponsored by University of Wisconsin, Madison.
NCT07624747 is a clinical trial that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07624747 is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether and how a person's brain changes in the first few months after starting gender affirming hormone therapy (GAHT). The investigators want to know if GAHT changes: 1) cerebral blood flow (CBF), 2) brain structure, connectivity, and cognitive task performance, and 3) neurocognitive function (memory, attention, executive function, processing speed). 36 male at birth and 36 female at birth participants will conduct baseline studies prior to GAHT, with a second identical set of study visits 4-6 months after GAHT begins.
Primary Outcome
CBF at rest and in response to cognitive stressors.
Interventions
- DEVICE Magnetic Resonance Imaging
- OTHER Cognition and Health Tests
- OTHER Optional Exercise Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2028-04 |
What NCT07624747 shows while recruiting
NCT07624747 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT07624747 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07624747 about?
NCT07624747 is a clinical study titled "Brain Health in Transgender Adults". The purpose of this study is to test whether and how a person's brain changes in the first few months after starting gender affirming hormone therapy (GAHT). The investigators want to know if GAHT changes: 1) cerebral blood flow (CBF), 2) brain structure, connectivity, and cognitive task performance...
What is the current status of trial NCT07624747?
This trial is currently recruiting. The enrollment target is 72 participants. The study started on 2025-10-14. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07624747?
The interventions under investigation include: Magnetic Resonance Imaging (DEVICE), Cognition and Health Tests (OTHER), Optional Exercise Test (OTHER).
Who is sponsoring clinical trial NCT07624747?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI